New York, June 3, 2026, 09:05 (EDT)
Mineralys Therapeutics shares fell before the bell on Wednesday after the company priced a $150 million common-stock offering at $26.50 a share to help fund a buyout of future royalties on its main hypertension drug. The stock was quoted at $26.35 at 9:00 a.m. EDT, down 8.7% from Tuesday’s Nasdaq close of $28.85; Mineralys said it would sell 5,660,378 shares, with the offering expected to close on or about June 4.
The selloff matters because Mineralys is raising equity just as investors weigh how much control it can keep over lorundrostat, its lead pill for uncontrolled or resistant high blood pressure. An aldosterone synthase inhibitor — a drug designed to lower production of aldosterone, a hormone that can push blood pressure higher — lorundrostat is under U.S. Food and Drug Administration review, with a target action date of December 22, 2026.
A filing showed Mineralys agreed to pay Tanabe Pharma $200 million upfront to end potential future royalty payments, or sales-linked payments owed to a drug licensor. The company also entered a five-year, senior secured term loan — debt backed by company assets — for up to $500 million from funds managed by Pharmakon Advisors, with the first $100 million drawn at closing and later tranches tied to FDA approval and sales milestones.
Chief Executive Jon Congleton said the Tanabe transaction would “eliminate all future royalty payments” and let Mineralys “capture meaningful incremental value” from potential lorundrostat sales. That is the trade investors are being asked to underwrite: dilution now, cleaner economics later. Mineralys Therapeutics, Inc.
The offering price was about 8% below Tuesday’s close, a common pressure point for biotechnology shares when companies sell stock. The banks running the deal are BofA Securities, Goldman Sachs and Evercore ISI, Mineralys said.
Mineralys had $646.1 million in cash, cash equivalents and investments at March 31 and reported a first-quarter net loss of $39.3 million. It said last month that existing funds were enough to support planned trials, regulatory work and operations into 2028, before the latest financing package.
There is fresh clinical material behind the timing. Mineralys presented new Phase 3 Launch-HTN data in patients with chronic kidney disease at a European hypertension meeting, saying lorundrostat showed placebo-adjusted systolic blood pressure reductions of 9.6 millimeters of mercury in participants with chronic kidney disease and 12.2 millimeters in those without it after 12 weeks. Dr. Liffert Vogt of Amsterdam University Medical Center said the findings showed “comparable blood pressure reductions” regardless of kidney disease status. BioSpace
Competition is no longer theoretical. AstraZeneca’s Baxfendy, also an aldosterone synthase inhibitor, won U.S. approval in May for adults with hypertension whose blood pressure is not adequately controlled, putting AstraZeneca ahead of Mineralys in the class, Reuters reported.
But the downside case is clear. The share sale dilutes current holders, the debt adds lender rules and interest, and future loan draws depend on milestones Mineralys has not yet hit. A delay, rejection or narrower-than-hoped FDA label for lorundrostat would leave the company with a bigger capital structure and no approved product to sell.
For now, the market reaction is about price. Mineralys is buying back future economics in its only lead asset, but investors are marking the stock closer to the new-money level first.
